The Discovery of LOX-1, its Ligands and Clinical Significance
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
LOX-1 is an endothelial receptor for oxidized low-density lipoprotein (oxLDL), a key molecule in the pathogenesis of atherosclerosis.The basal expression of LOX-1 is low but highly induced under the influence of proinflammatory and prooxidative stimuli in vascular endothelial cells, smooth muscle cells, macrophages, platelets and cardiomyocytes. Multiple lines of in vitro and in vivo studies have provided compelling evidence that LOX-1 promotes endothelial dysfunction and atherogenesis induced by oxLDL. The roles of LOX-1 in the development of atherosclerosis, however, are not simple as it had been considered. Evidence has been accumulating that LOX-1 recognizes not only oxLDL but other atherogenic lipoproteins, platelets, leukocytes and CRP. As results, LOX-1 not only mediates endothelial dysfunction but contributes to atherosclerotic plaque formation, thrombogenesis, leukocyte infiltration and myocardial infarction, which determine mortality and morbidity from atherosclerosis. Moreover, our recent epidemiological study has highlighted the involvement of LOX-1 in human cardiovascular diseases. Further understandings of LOX-1 and its ligands as well as its versatile functions will direct us to ways to find novel diagnostic and therapeutic approaches to cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734 · cited 1×
“It binds to various ligands exposed on damaged tissues or bacteria, promoting phagocytosis and complement activation [92, 93] and has long been used as an inflammatory biomarker [94].”
BackgroundRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850 · cited 1×
“Recent epidemiological studies have shown that even a slight increase in the serum concentration of CRP can be a major risk indicator for ischemic heart diseases [100–102].”
BackgroundInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging.
Pignoli, P., Tremoli, E., Poli, A., Oreste, P., & Paoletti, R. (1986) · Circulation · doi:10.1161/01.cir.74.6.1399 · Cited by 2,404
Black, S., Kushner, I., & Samols, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400025200 · Cited by 1,844
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Cited by
Condamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789
C-type lectins in immunity and homeostasis
Brown, G. D., Willment, J. A., & Whitehead, L. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0004-8 · Cited by 744
Role of Ox-LDL and LOX-1 in Atherogenesis
Kattoor, A. J., Kanuri, S. H., & Mehta, J. L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666180508100950 · Cited by 330
A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease
PrabhuDas, M. R., Baldwin, C. L., Bollyky, P. L., Bowdish, D. M. E., Drickamer, K., Febbraio, M., Herz, J., Kobzik, L., Krieger, M., Loike, J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700373 · Cited by 329
Self-citationLOX-1 in atherosclerosis: biological functions and pharmacological modifiers
Xu, S., Ogura, S., Chen, J., Little, P. J., Moss, J., & Liu, P. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1194-z · Cited by 293
Metadata
- Authors
- Yoshimoto, R., Fujita, Y., Kakino, A., Iwamoto, S., Takaya, T., & Sawamura, T.
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2011-08-02
- Volume
- 25
- Issue
- 5
- Pages
- 379-391
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W1981177667
- Cited by
- 154
- References
- 20
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Discovery of LOX-1, its Ligands and Clinical Significance. https://app.cochat.ai/papers/10.1007/s10557-011-6324-6
- The paper
- Yoshimoto, R., Fujita, Y., Kakino, A., Iwamoto, S., Takaya, T., & Sawamura, T. (2011). The Discovery of LOX-1, its Ligands and Clinical Significance. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-011-6324-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.